Cleared Traditional

K934869 - STC DIAGNOSTICS AUTO-LYTE BENZODIAZEPIN...

K934869 is the FDA 510(k) clearance for STC DIAGNOSTICS AUTO-LYTE BENZODIAZEPIN... by Solarcare Technologies Corp,Inc.. It is a Class 2 Toxicology device (product code JXM) cleared through the Traditional 510(k) pathway after a 41-day FDA review.

K934869 · Solarcare Technologies Corp,Inc. · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 1993
Decision
41d
Days
Class 2
Risk

K934869 is an FDA 510(k) clearance for the STC DIAGNOSTICS AUTO-LYTE BENZODIAZEPINES EIA. Classified as Enzyme Immunoassay, Benzodiazepine (product code JXM), Class II - Special Controls.

Submitted by Solarcare Technologies Corp,Inc. (Bethlehem, US). The FDA issued a Cleared decision on November 22, 1993 after a review of 41 days - a notably fast clearance cycle.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3170 - the FDA toxicology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Solarcare Technologies Corp,Inc. devices

Submission Details

510(k) Number K934869 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 12, 1993
Decision Date November 22, 1993
Days to Decision 41 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary Statement
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
46d faster than avg
Panel avg: 87d · This submission: 41d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code JXM Enzyme Immunoassay, Benzodiazepine
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3170
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - JXM Enzyme Immunoassay, Benzodiazepine

All 75
Devices cleared under the same product code (JXM) and FDA review panel - the closest regulatory comparables to K934869.
CX(TM) BENZODIAZEPINE(BENZ) REAGENT FOR SYCHRON CX SYS
K944076 · Beckman Instruments, Inc. · Nov 1994
CEDIA DAU BENZODIAZEPINE ASSAY
K942795 · Microgenics Corp. · Aug 1994
CEDIA DAU BENZODIAZEPINE ASSAY
K940159 · Microgenics Corp. · May 1994
BENZODIAZEPINE ENZYME IMMUNOASSAY
K930529 · Diagnostic Reagents, Inc. · Aug 1993
EMIT(R) D.A.U. BENZODIAZEPINE ASSAY
K931536 · Syva Co. · May 1993
EMIT(R) II BENZODIAZEPINE ASSAY
K926067 · Syva Co. · Jan 1993